Nectar Life Care has announced the launch of a new range of high-quality, cost-effective anti-diabetic formulations, with Dapagliflozin under the brand name DAPNEC. With the expiration of API patents, these medicines will now be available at affordable prices, enhancing accessibility while maintaining high efficacy.
India, often called the ‘Diabetes Capital of the World,’ faces a rising demand for effective diabetes management solutions. Type 2 diabetes, once prevalent among adults, is now increasingly affecting younger individuals due to sedentary lifestyles, poor dietary habits, and rising obesity rates. According to the Indian Council of Medical Research (ICMR), over 77 million people in India have diabetes, with a significant portion undiagnosed. Studies by the Indian Diabetes Risk Score (IDRS) indicate that more than 10% of urban Indian youth are at risk, underscoring the need for comprehensive and accessible healthcare solutions.
The product portfolio for Nectar ranges from essential anti-diabetic formulations to combination medications, offering comprehensive solutions for Type 2 diabetes management as prescribed by the physician. The range also includes:
• SITANEC M 50/500 & 50/1000 – Metformin and Sitagliptin Tablets
• METNEC-G1 & METNEC G2 – Metformin and Glimepiride Tablets
• METNEC 500mg – Metformin Tablets
Manufactured in a WHO-GMP-certified facility, the range is designed to meet international quality standards while ensuring affordability. The company reported INR 6.4 crores in sales last year, and is anticipating to cross the INR 15 crores mark this year with the introduction of its diabetes care portfolio. This expansion strengthens Nectar Lifecare’s presence in both domestic and international markets, reinforcing its position as a trusted partner for pharmaceutical distributors, exporters, and healthcare providers.
Speaking about the launch, Nilesh Patel, founder of Nectar Life Care, said, “In today’s fast-paced world, sedentary lifestyles, high stress, and unhealthy eating habits have led to a sharp rise in diabetes, particularly among the youth. With nearly 70% of India’s population residing in rural areas, access to affordable treatment remains a significant challenge. At Nectar Lifecare,
we are committed to addressing this gap. The launch of our cost-effective Dapagliflozin and upcoming diabetic formulations is a step toward ensuring quality diabetes care reaches those who need it most, regardless of financial constraints. Looking ahead, we plan to expand our portfolio with a dedicated anti-obesity range to combat the growing health risks associated with rising obesity. Our goal is to empower individuals to lead healthier lives by making essential treatments both accessible and affordable.”
Nectar Life Care’s product range will be available across India starting mid-February. With this launch, the brand continues to strengthen its position as a leader in affordable healthcare, bringing innovative and life-changing medicines to millions.
